Physician profile
Aurif Abedi
NPI 1922064922
$4,632.53
in general payments reported to CMS, 2019-2025
22 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $148 · 2020: $82.31 · 2022: $921 · 2023: $1,528 · 2024: $1,713 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,362 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,362.06 |
| Education | $119.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $998.57 | 2022-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $555.08 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $434.22 | 2022-2025 | Caplyta |
| Corium, LLC | $356.43 | 2023-2025 | Azstarys, Azstarys |
| Janssen Pharmaceuticals, INC | $344.27 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $340.34 | 2022-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $328.36 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $254.45 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $210.16 | 2023-2025 | Austedo Xr, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $156.30 | 2023-2024 | Quviviq |
| Alkermes, INC. | $120.65 | 2022-2025 | Lybalvi, Vivitrol |
| Merck Sharp & Dohme LLC | $118.51 | 2022-2023 | Belsomra |
| Vanda Pharmaceuticals INC. | $84.97 | 2022-2023 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $67.73 | 2022-2024 | Trintellix |
| Neurocrine Biosciences, INC. | $66.76 | 2022-2023 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $59.58 | 2022-2024 | Dyanavel Xr |
| Almatica Pharma LLC | $41.02 | 2022-2023 | Loreev Xr, Sertraline Hcl |
| Jazz Pharmaceuticals INC. | $32.60 | 2022 | |
| Neos Therapeutics, LP | $18.51 | 2023 | Adzenys Xr-Odt |
| Itamar Medical INC | $15.01 | 2025 | Watchpatone |
| Biohaven Pharmaceutical Holding Company LTD. | $14.54 | 2022 | |
| Owp Pharmaceuticals, INC. | $14.47 | 2023 | Lamotrigine, Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurif Abedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.